U.S. committee recommends GSK shingles vaccine over Merck rival

LONDON (Reuters) - The committee responsible for U.S. vaccination schedules has given a preferential recommendation to GlaxoSmithKline's newly approved shingles vaccine Shingrix over Merck & Co's established product Zostavax.

from Reuters: Health News http://ift.tt/2gDkvBz